Filtered By:
Drug: Tamoxifen

This page shows you your search results in order of date. This is page number 4.

Order by Relevance | Date

Total 50 results found since Jan 2013.

1366p * risk-benefit index of tamoxifen and raloxifene for chemoprevention of korean breast cancer
Conclusions: Women under the age 40 had more benefit than risk from tamoxifen chemoprevention. In the postmenopausal women with a uterus, raloxifene has more favorable risk-benefit index than tamoxifen.Disclosure: All authors have declared no conflicts of interest.
Source: Annals of Oncology - September 24, 2014 Category: Cancer & Oncology Authors: Chang, M. Tags: prevention and screening Source Type: research

De Novo Cerebrovascular Malformation in the Adult Mouse After Endothelial Alk1 Deletion and Angiogenic Stimulation Brief Reports
Conclusions— Deletion of Alk1 in EC in adult mice leads to an increased local EC proliferation during brain angiogenesis and de novo brain AVM.
Source: Stroke - February 24, 2014 Category: Neurology Authors: Chen, W., Sun, Z., Han, Z., Jun, K., Camus, M., Wankhede, M., Mao, L., Arnold, T., Young, W. L., Su, H. Tags: Cerebrovascular disease/stroke, Animal models of human disease, Genetically altered mice, Aneurysm, AVM, hematoma Brief Reports Source Type: research

Association of Tamoxifen Use and Reduced Cardiovascular Events Among Asian Females With Breast Cancer.
Conclusions: In Asian female breast cancer patients, tamoxifen use was associated with reduced risks of AMI, ischemic, hemorrhagic stroke and total cardiovascular events. PMID: 24107360 [PubMed - as supplied by publisher]
Source: Circulation Journal - October 9, 2013 Category: Cardiology Authors: Yang TL, Wu TC, Huang CC, Huang PH, Chung CM, Lin SJ, Chen JW, Chan WL, Chiang CH, Leu HB Tags: Circ J Source Type: research

Drugs to be offered to women at high risk of breast cancer
The National Institute of Health and Care Excellence (NICE) has today released updated guidelines on the care of women who are at increased risk of breast cancer due to their family history. One of the main changes to the original guidance from 2004 is that NICE now recommends drug treatment with tamoxifen or raloxifene to reduce risk of breast cancer in a specific group of women who are at high risk of breast cancer and have not had the disease. They say that these treatments could help prevent breast cancer in about 488,000 women aged 35 years and older. The updated guideline has also made changes to the recommende...
Source: NHS News Feed - June 25, 2013 Category: Consumer Health News Tags: Cancer Medical practice QA articles Source Type: news

Tamoxifen boost for breast cancer sufferers
Study finds that death rates fall significantly for patients who take the drug for 10 years rather than the standard fiveBreast cancer is less likely to recur if women previously treated for the disease take the drug tamoxifen for 10 years, instead of the recommended five, according to a British study. The study was a component of a larger international trial for which similar results were announced last year.Researchers estimated that, compared with taking no tamoxifen, 10 years of the drug reduces breast cancer death rates by a third in the first 10 years and by half after that. "Until now, there have been doubts whether...
Source: Guardian Unlimited Science - June 2, 2013 Category: Science Tags: The Guardian News Health Medical research Society Drugs UK news Breast cancer Science Source Type: news